This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

Oral once-daily dosing

Starting patients on Cibinqo1

For patients aged 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

Cibinqo 200 mg and 100 mg is a once-daily oral treatment

  • For most patients, particularly those with severe disease, 200 mg is the recommended starting dose
  • ​​​​​​​100 mg is the recommended starting dose for patients aged ≥65 years, for adolescents aged 12–17 years, and for those who have risk factors for developing an adverse reaction to Cibinqo or who are less likely to tolerate any adverse reactions

The dose may be decreased or increased based on tolerability and efficacy. 

  • Dose reduction can be considered after disease control is achieved in patients receiving 200 mg. Some patients may experience a disease flare after dose reduction. A higher risk of disease flare after dose reduction is associated with history of receiving systemic treatments for atopic dermatitis and extensive disease involving >50% of body surface area (BSA).

Cibinqo can be used with or without medicated topical therapies for atopic dermatitis

  • ​​​​​​​Discontinuation of treatment should be considered in patients who show no evidence of therapeutic benefit after 12 weeks.
  • Some patients with initial partial response may subsequently improve with continued treatment beyond 12 weeks

Cibinqo can be taken with or without food at approximately the same time each day

  • Taking Cibinqo with food may ease nausea if this is experienced by patients
  • Tablets should be swallowed whole with water and should not be split, crushed or chewed

• Treatment should not be initiated in patients with a platelet count <150 x 103/mm3, an absolute lymphocyte count (ALC) <0.5 x 103/mm3, an absolute neutrophil count (ANC) <1 x 103/mm3, or a haemoglobin value <8 g/dL

• 50 mg dose is available for dose adjustments in special populations, e.g. moderate to severe renal impairment or in case of drug–drug interactions. See the full Summary of Product Characteristics for specific dose adjustment instructions. The 50 mg dose was not studied in clinical trials


  • Hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics
  • Active serious systemic infections, including tuberculosis (TB)
  • Severe hepatic impairment
  • Pregnancy
    • There are no or limited amount of data on the use of abrocitinib in pregnant women. Studies in animals have shown reproductive toxicity. Abrocitinib has been shown to cause skeletal variations in the foetuses of pregnant rats and rabbits and to affect parturition and peri/postnatal development in rats. Cibinqo is contraindicated during pregnancy
  • Breastfeeding
    • There are no data on the presence of Cibinqo in human milk, the effects on the breast-fed infant, or the effects on milk production. Cibinqo was secreted in milk of lactating rats. A risk to newborns/infants cannot be excluded and Cibinqo is contraindicated during breastfeeding

Renal impairment

Mild (eGFR 60 to <90 mL/min)

Moderate (eGFR 30 to <60 mL/min)

Severe (eGFR <30 mL/min)

No dose adjustment required

The recommended dose of Cibinqo should be reduced by half to 100 mg or 50 mg once daily

50 mg once daily is the recommended starting dose. The maximum daily dose is 100 mg

Cibinqo has not been studied in patients with end-stage renal disease (ESRD) on renal replacement therapy.​​​​​​​

Hepatic impairment




No dose adjustment required

No dose adjustment required

Not studied, must not be used


The recommended starting dose for patients ≥65 years of age is 100 mg once daily.


The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. The safety and efficacy of Cibinqo in children under 12 years of age have not yet been established. No data are available.

Women of childbearing potential 

Women of reproductive potential should be advised to use effective contraception during treatment and for 1 month following the final dose of Cibinqo. Pregnancy planning and prevention for females of reproductive potential should be encouraged.


Drug–drug interactions may require dose modifications of Cibinqo



Clinical impact


Strong CYP2C19 inhibitors

fluvoxamine, fluconazole, fluoxetine and ticlopidine

Increased exposure to Cibinqo moiety

Reduce dose of Cibinqo by half to 100 mg or 50 mg once daily

Strong CYP2C19 or CYP2C9 inducers

rifampicin, apalutamide, efavirenz, enzalutamide, phenytoin

Decreased exposure to Cibinqo active moiety and may result in loss of or reduced clinical response

Concomitant use of Cibinqo is not recommended

MOA inhibitors

selegiline, isocarboxazid

Not studied in humans. Clinical impact not known

Caution should be exercised for concomitant use

Potential for Cibinqo to affect other medications

No clinically significant effects of Cibinqo were observed in drug interaction studies with oral contraceptives (e.g. ethinyl oestradiol/levonorgestrel).

​​​​​​​In vitro, Cibinqo is an inhibitor of P-gp. Co-administration of dabigatran etexilate (a P-gp substrate), with a single dose of Cibinqo 200 mg increased dabigatran AUCinf and Cmax by approximately 53% and 40%, respectively, compared with administration alone. Caution should be exercised for concomitant use of Cibinqo with dabigatran.

​​​​​​​The effect of Cibinqo on pharmacokinetics of other P-gp substrates has not been evaluated. Caution should be exercised as the levels of P-gp substrates with a narrow therapeutic index, such as digoxin and ciclosporin, may increase.


Explore more

Practical considerations

Learn more about monitoring patients on Cibinqo.

View requirements

Patient resources

Access resources to help you support your patients on Cibinqo.

View resources

CYP=cytochrome P; eGFR=estimated glomerular filtration rate; MOA=monoamine oxidase; P-gp=P glycoprotein.
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.
PP-CIB-GBR-0068. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from Patients treated with Cibinqo should be given the Patient Card.


  • Starting patients on Cibinqo
  • Contraindications
  • Special populations
  • Interactions with other medications

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021